Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1390 plus radiotherapy in WHO Grade 4 glioma
NCT05182905Phase 1Active, not recruiting
- Sponsor
- Ivy Brain Tumor Center
- Start
- May 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of azd1390 in malignant glioma, sponsored by Ivy Brain Tumor Center. Started May 2022; status: active, not recruiting.
02
Drugs
azd1390
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT05182905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182905.